Paris

• A phase 3 efficacy and safety study of fosmanogepix for the treatment of adult patients with invasive mold infections Recruiting
  2024-516216-16-00 5 2026-02-13 Invasive mold infections caused by Aspergillus spp., Fusarium spp., Lo
• A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease Recruiting
  2024-516966-12-00 4 2026-02-13 Alzheimer’s disease
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad … Recruiting
  2025-521124-29-00 10 2026-02-13 Non-Small Cell Lung Cancer
• TulmiSTAR-02: Phase I/II open-label study of tulmimetostat in combination with darolutamide vs. darolutamide, and tulmimetostat with abirat … Recruiting
  2025-521873-15-00 9 2026-02-09 Metastatic hormone-sensitive prostate cancer
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• Tarlatamab vs standard of care chemotherapy in patients with pre-treated advanced, pulmonary or gastroenteropancreatic poorly differentiated … Recruiting
  2024-515948-23-00 5 2026-02-06 Advanced pulmonary or gastroenteropancreatic poorly differentiated neu
• Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc … Recruiting
  2024-515765-34-00 5 2026-02-04 English First-line extensive-stage small-cell lung cancer (ES-SCLC)
• A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has … Recruiting
  2025-521636-10-00 4 2026-02-04 Progressive Forms of Multiple Sclerosis (PMS)
• Randomised, controlled phase II proof-of-concept trial to assess the efficacy of abaCavIr/lamivudine treatment on the interferon signature i … Recruiting
  2023-508611-22-00 4 2026-02-03 systemic lupus
• A Study to Assess the Long-Term Efficacy and Safety of Afimkibart (RO7790121) in Patients with Atopic Dermatitis who participated in previou … Recruiting
  2025-520771-59-00 4 2026-02-03 Atopic Dermatitis
• A multicenter phase 2 single-arm proof-of-concept trial assessing the efficacy and safety of Obinutuzumab in the treatment of non-infectious … Recruiting
  2023-508930-33-00 4 2026-01-30 Non-infectious active cryoglobulinemia vasculitis who are either refra
• A first-in-human study to determine a safe dose of the drug TD001 to treat patients with metastatic prostate cancer that expresses the PSMA … Recruiting
  2025-523273-41-00 7 2026-01-30 Metastatic castration-resistant prostate cancer
• NUCastle - Nintedanib treatment in Unicentric Castleman disease Recruiting
  2023-510253-42-00 4 2026-01-28 Adult patients aged 18 and over with unicentric hyalino-vascular Castl
• CombiChronoS - Effectiveness of a Combination of Chronotherapeutics for the Treatment of Major Depressive Episode (MDE) with Insomnia: A Mul … Recruiting
  2024-516371-32-00 5 2026-01-28 insomnia
• Long-Term Extension Study of Vosoritide to Treat Children with Hypochondroplasia Recruiting
  2024-517238-16-00 5 2026-01-28 Hypochondroplasia
• Testing two different drugs (sacituzumab-govitecan and trastuzumab-deruxtecan) combinations prescribed in an alterning pattern to patients w … Recruiting
  2025-521909-40-00 4 2026-01-28 Patients with metastatic or locally advanced HER2-low triple-negative
• Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or Af … Recruiting
  2025-522400-24-00 10 2026-01-27 Metastatic urothelial cancer
• FT819 in B-cell Mediated Autoimmune Diseases Recruiting
  2024-517397-25-00 1 2026-01-26 B-cell Mediated Autoimmune Diseases
• Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc … Recruiting
  2024-515023-11-00 5 2026-01-22 Advanced Clear Cell Renal Cell Carcinoma
• Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o … Recruiting
  2024-515658-26-00 5 2026-01-21 Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
• A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting
  2025-521917-24-00 5 2026-01-21 Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
• FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients prev … Recruiting
  2023-505781-28-00 4 2026-01-20 Patients with Waldenstrom macroglobulinemia and have received at least
• A dose-ranging randomized, open-label study evaluating the effect of bilateral intravitreal injection of GS010 at two dose levels on visual … Recruiting
  2025-523339-20-00 4 2026-01-20 Leber Hereditary Optic Neuropathy due to mutations in the mitochondria
• A study to learn about how well BAY 3401016 works in adults with Alport syndrome Recruiting
  2024-516471-33-00 4 2026-01-19 Alport Syndrome

Showing 553–576 of 2,322 trials